An interventional study of Standard flexible ureterorenoscope and Flexible ureterorenoscope with direct in-scope suction in Renal Stone Disease, sponsored by Hitit University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Hitit University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Kidney Calculi with a site in Turkey — 21 open to participants now, 22 under way, none of them phase 3. Kidney Calculi · Turkey.
Among the 48 studies in Kidney Calculi with a site in Turkey, this one is the 25th largest by planned enrollment of the 35 interventional ones that give a count, is one of 14 that started in 2026, is one of 32 with no phase, reaches primary completion later than 10 of the 21 other live ones, and was the 45th registered.
510 studies on the registry are indexed under Kidney Calculi; 147 are open to participants now.
Browse Kidney Calculi studies →21 of the 48 studies in Kidney Calculi with a site in Turkey are open now. Recruiting first, the newest first:
Aydin Adnan Menderes University · Sites in Turkey
Ages 18+
Hitit University · Sites in Turkey
Ages 18–75
Hitit University · Sites in Turkey
Ages 18+
Hitit University · Sites in Turkey
Ages 18–75
Antalya Health Sciences University · Sites in Turkey
Ages 18+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 88 Kidney Calculi studies recruiting now, 48 (55%) set no upper age limit and 23 (26%) stop at 75 or younger; 6 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 14 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is below the median of 86 across 392 interventional studies indexed under Kidney Calculi.
Median enrollment 90 across the 35 interventional studies, 184 across the 13 observational. Of the 18 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 48 has an industry lead sponsor. The 10 most frequent:
Hitit University is the lead sponsor of 87 studies on the registry; 28 are open to participants now.
Hitit University has 5 studies filed under Kidney Calculi — fewer than ten, so there is no comparison to draw.
9 of the studies in Kidney Calculi with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07763600Malatya Governor Research HospitalEffect of Anesthesia Type on Surgeon Workload During Endoscopic Kidney Stone Surgery | 2027-01 |
| NCT07512297University of GaziantepPain Control During ESWL Using Non-Opioid Analgesics | 2027-01-01 |
| NCT07721571Hitit UniversityNephrostomy Tract Infiltration for Pain Control After PCNL | 2027-01-11 |
| NCT07736924Emrah Kızılay2D:4D Digit Ratio and Urinary Stone Disease | 2027-01-31 |
| NCT07655050Hitit UniversityAntibiotic Irrigation and Suction Ureteral Access Sheath in RIRS | 2027-02-08 |
Add all 9 to your calendar (.ics) → With an account.
Among the 48 studies in Kidney Calculi with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective study aims to compare the clinical, perioperative, and postoperative outcomes of flexible ureterorenoscopy using a direct in-scope suction system (DISS) with standard flexible ureterorenoscopy in patients undergoing retrograde intrarenal surgery for renal or proximal ureteral stones. A total of 70 patients will be enrolled, with 35 patients in each group. The study will assess postoperative infectious complications, including fever, systemic inflammatory response syndrome (SIRS), and sepsis, as well as operative parameters, length of hospital stay, reoperation, and stone-free status. Stone-free status will be assessed by non-contrast computed tomography four weeks after surgery.
Retrograde intrarenal surgery (RIRS) is used to treat renal and proximal ureteral stones. During flexible ureterorenoscopy, stone fragments and irrigation fluid may impair visualization, and elevated intrarenal pressure may contribute to postoperative infectious complications. Direct in-scope suction (DISS) permits aspiration through the ureterorenoscope during irrigation and lithotripsy. This study will compare procedural and postoperative outcomes with and without DISS.
This single-center, prospective, randomized, parallel-group study will enroll 70 adults undergoing RIRS at Erol Olçok Training and Research Hospital. Participants will be assigned in a 1:1 ratio to standard flexible ureterorenoscopy or DISS-equipped flexible ureterorenoscopy using a computer-generated randomization sequence. Each group will include 35 participants. Clinical data will be collected during surgery and postoperative follow-up.
The standard group will undergo surgery using a 7.5 Fr Storz Flex-X2 flexible ureterorenoscope. The DISS group will undergo surgery using a 7.5 Fr single-use Claritron flexible ureterorenoscope with direct in-scope suction. Both groups will use a 9.5/11.5 Fr ureteral access sheath, guidewire, Holmium:YAG laser lithotripsy, and normal saline irrigation. Procedures will be performed under general anesthesia in the lithotomy position, with the irrigation bag positioned approximately 100 cm above the patient.
Eligible patients will be aged 18 years or older and undergo RIRS by the same surgical team for a single renal or proximal ureteral stone. Patients with multiple stones, pregnancy, preoperative urinary tract infection, or bleeding diathesis will be excluded.
Demographic and stone characteristics, operative time, fluoroscopy time, total laser energy, length of hospital stay, and need for reoperation will be recorded. Laboratory results, including white blood cell count, C-reactive protein, and creatinine, as well as urine and blood culture results when obtained, will be collected during follow-up.
The primary outcomes are postoperative fever, systemic inflammatory response syndrome (SIRS), and sepsis. Fever is defined as a body temperature >38°C within 48 hours after surgery. SIRS is defined as the presence of at least two of the following: temperature >38°C or \<36°C, heart rate >90 beats/min, respiratory rate >20 breaths/min, or white blood cell count >12,000/mm³ or \<4,000/mm³. For this protocol, sepsis is defined as SIRS with suspected or confirmed infection. For patients who develop infectious complications, treatment, intravenous antibiotic use, and intensive care requirements will be recorded.
Secondary outcomes include stone-free status on non-contrast computed tomography approximately four weeks after surgery, postoperative changes in white blood cell count and creatinine, and postoperative culture findings. Residual fragments ≤4 mm will be classified as clinically insignificant for the study's stone-free assessment.
The two groups will be compared using tests appropriate for the distribution and type of each variable. Categorical data will be reported as counts and percentages. A p value \<0.05 will be considered statistically significant.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants randomized to this arm will undergo retrograde intrarenal surgery using a 7.5 Fr Storz Flex-X2 flexible ureterorenoscope without direct in-scope suction. A 9.5/11.5 Fr ureteral access sheath, Holmium:YAG laser lithotripsy, and normal saline irrigation will be used.
Device: Standard flexible ureterorenoscope
Participants randomized to this arm will undergo retrograde intrarenal surgery using a 7.5 Fr single-use Claritron flexible ureterorenoscope equipped with direct in-scope suction. A 9.5/11.5 Fr ureteral access sheath, Holmium:YAG laser lithotripsy, and normal saline irrigation will be used.
Device: Flexible ureterorenoscope with direct in-scope suction
A 7.5 Fr reusable Storz Flex-X2 flexible ureterorenoscope without direct in-scope suction will be used for retrograde intrarenal surgery. Stone fragmentation will be performed with a Holmium:YAG laser through a 9.5/11.5 Fr ureteral access sheath.
A 7.5 Fr single-use Claritron flexible ureterorenoscope equipped with direct in-scope suction will be used for retrograde intrarenal surgery. Suction through the scope will be available during irrigation and Holmium:YAG laser lithotripsy. A 9.5/11.5 Fr ureteral access sheath will be used.
Incidence of Postoperative Fever
Number and percentage of participants with a recorded body temperature \>38°C within 48 hours after surgery.
Time frame: Within 48 hours after surgery
Incidence of Postoperative Systemic Inflammatory Response Syndrome
Number and percentage of participants meeting at least two of the following criteria: temperature \>38°C or \<36°C, heart rate \>90 beats/min, respiratory rate \>20 breaths/min, or white blood cell count \>12,000/mm³ or \<4,000/mm³.
Time frame: Within 48 hours after surgery
Incidence of Postoperative Sepsis
Number and percentage of participants with suspected or confirmed infection who also meet the protocol-defined systemic inflammatory response syndrome criteria.
Time frame: Within 48 hours after surgery
Stone-Free Rate
Number and percentage of participants with no residual stone or residual fragments ≤4 mm on non-contrast computed tomography.
Time frame: 4 weeks after surgery
Plan to share: No
Started Jul 2026 (actual). Primary completion is estimated for Oct 2026, 3 months after the start.
Of 183 non-industry interventional studies with no phase under Kidney Calculi, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 54. This study's planned 3 months is below that.
Counting every sponsor, half of 199 studies reached it within 26 months; a quarter within 12 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hitit University